Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection

被引:17
作者
Pockros, PJ
Tong, M
Lee, WM
van Leeuwen, DJ
Keeffe, EB
Bala, K
Killenberg, PG
Foust, RT
Rosenblate, HJ
Payne, KM
Fromm, H
Lesesne, HR
Black, M
机构
[1] Scripps Clin, Div Gastroenterol Hepatol, La Jolla, CA 92137 USA
[2] Huntington Mem Hosp, Pasadena, CA USA
[3] Univ Texas, SW Med Sch, Dallas, TX 75230 USA
[4] Univ Alabama Hosp, Birmingham, AL USA
[5] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[6] St Bernardine Liver Dis Ctr, San Bernardino, CA USA
[7] Duke Univ, Med Ctr, Durham, NC USA
[8] Med Univ S Carolina, Charleston, SC 29425 USA
[9] Rush N Shore Med Ctr, Skokie, IL USA
[10] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[11] George Washington Univ, Washington, DC USA
[12] Univ N Carolina Hosp, Chapel Hill, NC USA
[13] Temple Univ Hosp, Philadelphia, PA 19140 USA
关键词
ALT; clinical study; consensus interferon; HCV infection; HCV RNA; interferon;
D O I
10.1046/j.1365-2893.1998.00114.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We have investigated the relationship between serum alanine aminotransferase (ALT) and hepatitis C virus (HCV) RNA in the assessment of responses to interferon (IFN) therapy in chronic HCV infection. Data from 704 patients with HCV infection who were randomized to receive consensus IFN-alpha (CIFN) 3 mu g (n=232 patients) or 9 mu g (n=232 patients), or IFN-alpha 2b 3 million units (MU) (n = 240 patients), were used for these analyses. All patients were treated three times weekly for 24 weeks and then were observed for a further 24 weeks. Hepatitis C viral RNA (HCV RNA) was determined by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) with a lower limit of detection of 100 copies ml(-1). Of patients with normal serum ALT concentrations, 53% (120/225) had undetectable HCV RNA at the end-of-treatment period and 47% (51/109) had undetectable HCV RNA at the end of the post-treatment observation period. In contrast, of the patients with undetectable HCV RNA, 75% (120/161) and 84% (51/61) had normal serum ALT activities at the end-of-treatment and post-treatment observations periods, respectively. The majority of patients with undetectable HCV RNA had normal ALT values. In contrast, only half of the patients with normal ALT values were negative for HCV. End-of-treatment HCV RNA response also better predicted sustained virological response than did end-of-treatment ALT response.
引用
收藏
页码:271 / 276
页数:6
相关论文
共 14 条
[1]  
Alton K., 1983, BIOL INTERFERON SYST, P119
[2]   The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon [J].
Blatt, LM ;
Davis, JM ;
Klein, SB ;
Taylor, MW .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1996, 16 (07) :489-499
[3]  
CASTILLO I, 1994, HEPATOLOGY, V19, P1342, DOI 10.1016/0270-9139(94)90225-9
[4]   TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL [J].
DAVIS, GL ;
BALART, LA ;
SCHIFF, ER ;
LINDSAY, K ;
BODENHEIMER, HC ;
PERRILLO, RP ;
CAREY, W ;
JACOBSON, IM ;
PAYNE, J ;
DIENSTAG, JL ;
VANTHIEL, DH ;
TAMBURRO, C ;
LEFKOWITCH, J ;
ALBRECHT, J ;
MESCHIEVITZ, C ;
ORTEGO, TJ ;
GIBAS, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1501-1506
[5]  
DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A
[6]   HIGH-RATE OF INFECTIVITY AND LIVER-DISEASE IN BLOOD-DONORS WITH ANTIBODIES TO HEPATITIS-C VIRUS [J].
ESTEBAN, JI ;
LOPEZTALAVERA, JC ;
GENESCA, J ;
MADOZ, P ;
VILADOMIU, L ;
MUNIZ, E ;
MARTINVEGA, C ;
ROSELL, M ;
ALLENDE, H ;
VIDAL, X ;
GONZALEZ, A ;
HERNANDEZ, JM ;
ESTEBAN, R ;
GUARDIA, J .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (06) :443-449
[7]   TREATMENT OF CHRONIC NON-A,NON-B HEPATITIS WITH RECOMBINANT HUMAN ALPHA-INTERFERON - A PRELIMINARY-REPORT [J].
HOOFNAGLE, JH ;
MULLEN, KD ;
JONES, DB ;
RUSTGI, V ;
DIBISCEGLIE, A ;
PETERS, M ;
WAGGONER, JG ;
PARK, Y ;
JONES, EA .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (25) :1575-1578
[8]   SIGNIFICANCE OF SERUM HEPATITIS-C VIRUS-RNA LEVELS IN CHRONIC HEPATITIS-C [J].
LAU, JYN ;
DAVIS, GL ;
KNIFFEN, J ;
QIAN, KP ;
URDEA, MS ;
CHAN, CS ;
MIZOKAMI, M ;
NEUWALD, PD ;
WILBER, JC .
LANCET, 1993, 341 (8859) :1501-1504
[9]  
MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1002/hep.1840220406
[10]   A COMPARISON OF INTERFERON-CON1 WITH NATURAL RECOMBINANT INTERFERONS-ALPHA - ANTIVIRAL, ANTIPROLIFERATIVE, AND NATURAL KILLER-INDUCING ACTIVITIES [J].
OZES, ON ;
REITER, Z ;
KLEIN, S ;
BLATT, LM ;
TAYLOR, MW .
JOURNAL OF INTERFERON RESEARCH, 1992, 12 (01) :55-59